Suggestions
Omar Barnaby, Ph.D.
Senior Principal Scientist at Amgen
Omar Barnaby, Ph.D. is a Senior Principal Scientist at Amgen with extensive experience in the biotechnology industry.1 He is a scientific leader with 8 years of industry experience, specializing in analytical chemistry and bioanalysis.1
Professional Background
Dr. Barnaby is an expert in LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) techniques, with a focus on developing quantitative assays for measuring drugs and biomarkers in biological matrices. His expertise extends to:
- Leading LC-MS/MS bioanalytical efforts for biomarker studies and oligonucleotides
- Developing oligonucleotide characterization methods
- Creating LC-MS workflows for intact proteins
- Quantifying drug targets to support research programs
Education
- Ph.D. in Analytical Chemistry from the University of Nebraska-Lincoln
- BSc in Chemistry and Physics from Warren Wilson College
Research Impact
Dr. Barnaby's work has been widely recognized in the scientific community. According to Google Scholar, he has been cited 1,204 times for his contributions to bioanalysis and LC-MS research.3
Career Progression
Before his current role as Senior Principal Scientist at Amgen, Dr. Barnaby held positions such as:
- Senior Scientist and GLP Principal Investigator in the biotechnology industry
- Principal Scientist at Amgen3
His LinkedIn profile (username: obarnaby) provides a platform for professional networking and sharing insights in his field of expertise.12
Highlights
Hoping to see some familiar (and new) faces at the upcoming @AAPSComms PharmSci 360 meeting (#PharmSci360). Join me at my session [Clinical Bioanalysis of Maridebart Cafraglutide (Formerly AMG 133), a Bispecific Molecule for Obesity]: https://lnkd.in/gUpNKbuT
Thrilled to give a Rapid Fire presentation on Intact Protein Quantification by HRMS (Q-Exactive HFx) at the 2020 AAPS meeting. We demonstrate:
-
Multiplexed quantification of mAb therapeutics (PK) with a single analytical method and unrestricted by analyte concentration differences (100 - 5000 ng/mL from 30uL plasma); a potential limitation of multiplexed LBA approaches.
-
Reproducible chromatographic performance, Accuracy/Precision, and comparable PK (Discreet analysis/orthogonal methods).
-
A simple workflow with generic IP reagents, automated sample preparation, and chromatographic timescales typical of surrogate peptide workflows.
-
Data processing workflows with #Thermo Chromeleon, which is a potential path forward for regulated Bioanalysis on this HRMS platform.
Hoping to interact with you at the conference: November 3 at 9:45 AM (Eastern)/6:45 AM (Western). Many thanks to Todd Hager, Zhe Wang, John Zobac, and Tom Dillon for putting this into action.
#Amgen #Biotechnology #Innovation #Stem #mycompany
https://lnkd.in/ennRRWQ
